^
Association details:
| Biomarker: | EML4-ALK fusion + TMB-L |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
Published date:
03/31/2023
Excerpt:
A left submandibular biopsy revealed SCLC. Echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion and low tumor mutation burden (2.23 muts/Mb) were identified by next generation sequencing. The patient was administered atezolizumab (1,200 mg, d1) in combination with etoposide (0.13 g, d1-d3) and carboplatin (350 mg, d1). The left neck mass was reduced significantly, showing a partial response.
Secondary therapy:
carboplatin + etoposide oral
DOI:
10.21037/tlcr-23-154
